ICE方案治疗晚期非小细胞肺癌的临床观察

目的:观察异环磷酰胺(IFO)、顺铂(DDP)、依托泊苷(Vp16)联合化疗治疗晚期非小细胞肺癌(nonsmall cell lungcancer,NSCLC)的效果和不良反应。方法:IFO2g,持续4h静脉滴入,d1～d3;DDP25mg/m2,静脉滴入,d1～d3;Vp1680mg/m2,静脉滴入,d1～d3。每28d为1个周期。结果:48例总有效率为43.75%,鳞癌27例有效率为59.26%,腺癌21例有效率为23.81%,两者差异有统计学意义,u=2.783,P=0.0054;中位生存期8.6个月,1年生存率为25%,2年生存率为9.1%;不良反应主要是骨髓抑制,其次为消化道反应和脱发。结论:ICE方案治疗NSCLC可获得较好的远近期效果(鳞癌优于腺癌),但需注意其易出现骨髓抑制的不良反应。

Clinical study on efficacy of patients with non-small cell lung cancer treated with ICE regimen

OBJECTIVE:To investigate the efficacy and toxicity of patients with non-small cell lung cancer (NSCLC) treated with cisplatin-based combination chemotherapy regimens:ifosfamide, cisplatin and etoposide regimen (ICE). METHODS:Ifosfamide was administered intravenously in a dose of 2 g for four hours from Day 1 to Day 3. DDP was given in a dose of 25 mg/m2 intravenously (Vp-16 80 mg/m2) from day 1 to day 3. This combination was repeated every 28 days. RESULTS:The response rate for the whole group was 43.75%.The response rate of squamaous cancer of 27 cases was 59.26%; the response rate of glandular cancer of 21 cases was 23.81%.There was a significant difference between them,u=2.783,P=0.005 4. Median survival of response was 8.6 months, the survival rate of one year was 25%, the one of two years was 9.1%. The major toxicity was myelosupression,and other toxicities included loss of appetite, nausea/vomiting, stomatites and alopecia.CONCLUSIONS:ICE is a good long-dated effective regimen for the patients with NSCLC, but meanwhile, it is easy to have the toxicity of myelosupression.